Acelyrin down 54% on disastrous izokibep data

13 September 2023
acelyrin_big

US immunology specialist Acelyrin (Nasdaq: SLRN) lost a whopping 54% of its stock market value on Tuesday.

The Californian company - which was riding high in May on raising $540 million in an initial public offering - had announced top-line results from Part B of a Phase IIb/III trial evaluating izokibep for the treatment of moderate-to-severe hidradenitis suppurativa (HS).

The primary endpoint of HiSCR75 (hidradenitis suppurativa clinical response) at week 16 did not meet statistical significance. Acelyrin’s cause was not helped by a high drop-out rates.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology